Back to Search Start Over

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

Authors :
Harter, Philipp
Hauke, Jan
Heitz, Florian
Reuss, Alexander
Kommoss, Stefan
Marme, Frederik
Heimbach, Andre
Prieske, Katharina
Richters, Lisa
Burges, Alexander
Neidhardt, Guido
de Gregorio, Nikolaus
El-Balat, Ahmed
Hilpert, Felix
Meier, Werner
Kimmig, Rainer
Kast, Karin
Sehouli, Jalid
Baumann, Klaus
Jackisch, Christian
Park-Simon, Tjoung-Won
Hanker, Lars
Kroeber, Sandra
Pfisterer, Jacobus
Gevensleben, Heidrun
Schnelzer, Andreas
Dietrich, Dimo
Neunhoeffer, Tanja
Krockenberger, Mathias
Brucker, Sara Y.
Nuernberg, Peter
Thiele, Holger
Altmueller, Janine
Lamla, Josefin
Elser, Gabriele
du Bois, Andreas
Hahnen, Eric
Schmutzler, Rita
Harter, Philipp
Hauke, Jan
Heitz, Florian
Reuss, Alexander
Kommoss, Stefan
Marme, Frederik
Heimbach, Andre
Prieske, Katharina
Richters, Lisa
Burges, Alexander
Neidhardt, Guido
de Gregorio, Nikolaus
El-Balat, Ahmed
Hilpert, Felix
Meier, Werner
Kimmig, Rainer
Kast, Karin
Sehouli, Jalid
Baumann, Klaus
Jackisch, Christian
Park-Simon, Tjoung-Won
Hanker, Lars
Kroeber, Sandra
Pfisterer, Jacobus
Gevensleben, Heidrun
Schnelzer, Andreas
Dietrich, Dimo
Neunhoeffer, Tanja
Krockenberger, Mathias
Brucker, Sara Y.
Nuernberg, Peter
Thiele, Holger
Altmueller, Janine
Lamla, Josefin
Elser, Gabriele
du Bois, Andreas
Hahnen, Eric
Schmutzler, Rita
Publication Year :
2017

Abstract

Background Identification of families at risk for ovarian cancer offers the opportunity to consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially affected families in Germany was solely performed via family history and numbers of affected family members with breast or ovarian cancer. However, neither the prevalence of deleterious variants in BRCA1/2 in ovarian cancer in Germany nor the reliability of family history as trigger for genetic counselling has ever been evaluated. Methods Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included 25 candidate and established risk genes. Among these 25 genes, 16 genes (ATM, BRCA1, BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, NBN, PMS2, PTEN, PALB2, RAD51C, RAD51D, STK11, TP53) were defined as established cancer risk genes. A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history. Results In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years (range 16-93) and 406 patients (77.6%) had a high-grade serous ovarian cancer. In total, 27.9% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4% in the defined 16 risk genes. Deleterious variants were most prevalent in the BRCA1 (15.5%), BRCA2 (5.5%), RAD51C (2.5%) and PALB2 (1.1%) genes. The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse. The prevalence of deleterious variants in BRCA1/2 (and in all 16 risk genes) in patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients >= 60 years. Family history was positive in 43% of all patients. Patients with a positive family history had a prevalence of de

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1364916487
Document Type :
Electronic Resource